07/10/2021 | Press release | Distributed by Public on 07/10/2021 05:22
Basel, October 7, 2021 - Novartis announced today it will present 41 abstracts at the upcoming 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), taking place digitally on October 13-15, 2021. The data being presented spans a comprehensive MS portfolio, emphasizing the company's commitment to improving the quality of life for people living with MS at all stages of the disease.
"These data strengthen the role of Kesimpta as a first-choice treatment for relapsing forms of MS, highlighting its long-term safety and efficacy for patients and physicians," said Lykke Hinsch Gylvin, Neuroscience Global Medical Franchise Head, Novartis Pharmaceuticals. "With new data across our MS portfolio, Novartis is committed to reimagining medicine by leading on new treatment options, challenging ourselves to focus on unmet needs when managing the disease, and ultimately improving the lives of people living with MS."
In addition to the data presented at ECTRIMS, Novartis will initiate Phase III pivotal trials to investigate remibrutinib in RMS patients. Remibrutinib (LOU064) is a highly selective and potent covalent BTK inhibitor with a potential best-in-class profile and has shown favorable safety based on clinical data established to date.1
BTK inhibitors are a novel class of therapies that target B-cells and other innate immune cells and prevent inflammation and potentially disease progression in MS.
Novartis key highlights at the 37th ECTRIMS Congress include:
New efficacy and safety data on Kesimpta, the first and only self-administered, targeted B-cell therapy for patients with relapsing forms of MS (RMS), show that Kesimpta is a well-tolerated, high-efficacy therapy in adults, including newly diagnosed patients, with RMS. The study results will provide a robust picture of safety data for Kesimpta after extended exposure (~ 3.5 years):
New data on Mayzent, the first and only oral treatment studied and proven to slow disability progression as demonstrated in the EXPAND study that included a broad range of secondary progressive MS (SPMS) patients, add to the growing body of evidence that patients treated with Mayzent show delays in disability progression and experience benefits in cognitive performance:
Novartis in Neuroscience
At Novartis Neuroscience, we have been tackling neurological conditions for more than 80 years, launching transformative treatments which have made meaningful differences to millions of people worldwide. We continue to collaborate on industry-leading treatments in multiple sclerosis, pediatric neurology, neurodegeneration and neuropsychiatry because we know through innovation, partnership and community engagement early on, we can improve the standard of care.
To ensure patients everywhere can benefit from these life-changing therapies, we work closely with key stakeholders across the world to ensure rapid and sustainable access to our medicines, with the aim of providing the widest choice of treatments for each person's unique journey.
Disclaimer
This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.
About Novartis
Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact [email protected]
References
# # #
Novartis Media Relations
E-mail: [email protected]
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: [email protected]
Central | North America | ||
Samir Shah | +41 61 324 7944 | Sloan Simpson | +1 862 345 4440 |
Thomas Hungerbuehler | +41 61 324 8425 | Alina Levchuk | +1 862 778 3372 |
Isabella Zinck | +41 61 324 7188 | Parag Mahanti | +1 973-876-4912 |